Answers are grounded in this paper and cite their sources.
Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
No takes yet. Share an insight, caveat, or question.
Trapani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: